Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism
Arata Fukushima, … , Ivan M. Rebeyka, Gary D. Lopaschuk
Arata Fukushima, … , Ivan M. Rebeyka, Gary D. Lopaschuk
Published May 17, 2018
Citation Information: JCI Insight. 2018;3(10):e99239. https://doi.org/10.1172/jci.insight.99239.
View: Text | PDF
Research Article Metabolism

Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism

  • Text
  • PDF
Abstract

A dramatic increase in cardiac fatty acid oxidation occurs following birth. However, cardiac hypertrophy secondary to congenital heart diseases (CHDs) delays this process, thereby decreasing cardiac energetic capacity and function. Cardiac lysine acetylation is involved in modulating fatty acid oxidation. We thus investigated what effect cardiac hypertrophy has on protein acetylation during maturation. Eighty-four right ventricular biopsies were collected from CHD patients and stratified according to age and the absence (n = 44) or presence of hypertrophy (n = 40). A maturational increase in protein acetylation was evident in nonhypertrophied hearts but not in hypertrophied hearts. The fatty acid β-oxidation enzymes, long-chain acyl CoA dehydrogenase (LCAD) and β-hydroxyacyl CoA dehydrogenase (βHAD), were hyperacetylated and their activities positively correlated with their acetylation after birth in nonhypertrophied hearts but not hypertrophied hearts. In line with this, decreased cardiac fatty acid oxidation and reduced acetylation of LCAD and βHAD occurred in newborn rabbits subjected to cardiac hypertrophy due to an aortocaval shunt. Silencing the mRNA of general control of amino acid synthesis 5-like protein 1 reduced acetylation of LCAD and βHAD as well as fatty acid oxidation rates in cardiomyocytes. Thus, hypertrophy in CHDs prevents the postnatal increase in myocardial acetylation, resulting in a delayed maturation of cardiac fatty acid oxidation.

Authors

Arata Fukushima, Liyan Zhang, Alda Huqi, Victoria H. Lam, Sonia Rawat, Tariq Altamimi, Cory S. Wagg, Khushmol K. Dhaliwal, Lisa K. Hornberger, Paul F. Kantor, Ivan M. Rebeyka, Gary D. Lopaschuk

×

Figure 1

Overall acetylation of cardiac protein in neonatal human hearts, and postnatal alterations in sirtuins and acetyltransferases.

Options: View larger image (or click on image) Download as PowerPoint
Overall acetylation of cardiac protein in neonatal human hearts, and pos...
(A and B) Representative immunoblots of total protein acetylation and its densitometric analysis normalized to tubulin (n = 6/group). (C–I) Representative immunoblots of sirtuin 1–6 (SIRT1–6) and their densitometric analysis normalized to tubulin (n = 6/group, C–E and G; n = 8/group, F), (C, J and K) Representative immunoblots of nuclear acetyltransferase general control of amino acid synthesis 5 (GCN5) (n = 6/group, J), mitochondrial acetyltransferase GCN5-like protein 1 (GCN5L1, n=9/group, K) and their densitometric analysis normalized to tubulin. All lanes were run on the same gel but were noncontiguous, except for SIRT2, SIRT6, GCN5, and GCN5L1, which were from different gels for each group (hypertrophy/nonhypertrophied). Values represent mean ± SEM. *P < 0.05, 2-way ANOVA, comparing ages 21–100 days and 101–200 days in the same group. Black circles denote age of 21–100 days, and white circles denote age of 101–200 days.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts